358674-74-5Relevant academic research and scientific papers
GLP-1 RECEPTOR MODULATORS
-
Paragraph 0010781, (2016/06/28)
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION
-
Page/Page column 50; 51, (2010/08/08)
The invention relates to new piperazine-pieridine compounds having anti-viral activity and particularly anti-HCV activity. The invention further relates to pharmaceutical compositions comprising compounds according to the invention.
Synthesis of potent and selective dopamine D4 antagonists as candidate radioligands
Huang, Yiyun,Kegeles, Lawrence S.,Bae, Sung-A,Hwang, Dah-ren,Roth, Bryan L.,Savage, Jason E.,Laruelle, Marc
, p. 1375 - 1377 (2007/10/03)
A series of dopamine D4 antagonists was synthesized and evaluated as potential candidates for development as positron emission tomography (PET) radioligands. All new compounds display high affinity and selectivity for the D4 receptors and compounds 5b, 5d, and 5e were identified as candidates for radioligand development.
